ProPhase Labs, Inc.
PRPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000868278
No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding ProPhase Labs, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 32 | 29 | −3 |
| Shares | 1.70M | 1.74M | +42.0K (+2.5%) |
| Value | $11.0M | $7.27M | −$3.71M (−33.8%) |
New holders (3)
Institutions that held ProPhase Labs, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Adviser Investments LLC | 22,000 | $92.0K | 0.00% |
| Barclays PLC | 11,767 | $49.2K | 0.00% |
| Group One Trading, L.P. | 705 | $2.95K | 0.00% |
Sold out (6)
Institutions that held ProPhase Labs, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Goldman Sachs Group Inc | 23,786 | $153.9K |
| Tower Research Capital LLC (TRC) | 10,568 | $68.4K |
| UBS Group AG | 3,323 | $21.5K |
| Proequities, Inc. | 292 | $1.89K |
| Capital Advisors, Ltd. LLC | 190 | $1.00K |
| Spire Wealth Management | 80 | $518 |